What is the difference between semaglutide, tirzepatide and retatrutide?

Semaglutide is a GLP-1 receptor mono-agonist, tirzepatide is a dual GIP/GLP-1 receptor agonist, and retatrutide adds glucagon receptor agonism as a triple agonist. They differ in which receptor arms they engage rather than in fundamental class.

Why do GLP-1 analogs need low-bind labware?

Acylated analogs are surface-active and adsorb to standard glass and plastic at low concentrations, producing apparent potency loss that is a handling artefact rather than compound degradation.

What is cagrilintide's mechanism relative to GLP-1 analogs?

Cagrilintide is a long-acting amylin analog acting at calcitonin and amylin receptor complexes — a satiety-signalling axis distinct from the incretin receptors engaged by GLP-1 analogs.

Compound classes · 9 min read

GLP-1 receptor agonists in metabolic research

How single, dual and triple incretin receptor agonists differ mechanistically, and why half-life engineering rather than receptor affinity distinguishes most current analogs.

The incretin axis

Glucagon-like peptide-1 is an incretin hormone released from intestinal L-cells in response to nutrient intake. It acts at the GLP-1 receptor, a class B G-protein-coupled receptor, coupling primarily to Gs and raising intracellular cAMP. Native GLP-1 is cleaved by dipeptidyl peptidase-4 within minutes, which is why the unmodified hormone has almost no utility as a research tool for sustained exposure work.

Every therapeutic-class analog in circulation is a solution to that clearance problem. Substitution at position 8 blocks DPP-4 cleavage; fatty-acid acylation confers reversible albumin binding that extends circulating half-life from minutes to days. The receptor pharmacology is largely conserved — what changes is exposure.

Single, dual and triple agonism

Semaglutide is a mono-agonist selective for GLP-1R, carrying an alpha-aminoisobutyric acid substitution at position 8 and a C18 diacid linked through a spacer at position 26. Tirzepatide is a dual GIP/GLP-1 receptor agonist built on a GIP backbone, with reported bias toward GIP receptor activity relative to GLP-1. Retatrutide adds glucagon receptor agonism, making it a triple GIP/GLP-1/GCGR agonist.

The pharmacological interest in adding receptors is not additive potency but divergent downstream biology: GIP receptor activation modulates adipocyte behaviour and appears to attenuate GLP-1-associated emetic signalling in preclinical models, while glucagon receptor agonism contributes an energy-expenditure component absent from the incretin arms.

Amylin analogs and combination work

Cagrilintide is a long-acting amylin analog acting at calcitonin and amylin receptor complexes — a different axis entirely from the incretins, mediating satiety signalling through the area postrema. CagriSema combines cagrilintide with semaglutide, and in preclinical literature the combination is studied specifically for non-overlapping mechanism rather than dose escalation of either component.

In comparative in vitro work this matters methodologically. Receptor-selective readouts must be chosen to isolate the arm being interrogated, because a cAMP assay in a cell line expressing multiple receptors of the class cannot attribute signal to a single receptor.

Handling considerations for this class

Acylated analogs are surface-active and adsorb readily to glass and plastic at low concentrations, which produces apparent potency loss that is a handling artefact rather than degradation. Low-bind labware and a carrier protein in the diluent mitigate this in dilute work.

These compounds are also aggregation-prone at high concentration under agitation. Reconstitute slowly, avoid vortexing, and inspect for opalescence before use — a faint haze in a solution that was clear yesterday is fibrillation, not a lighting artefact.

Frequently asked questions

What is the difference between semaglutide, tirzepatide and retatrutide?: Semaglutide is a GLP-1 receptor mono-agonist, tirzepatide is a dual GIP/GLP-1 receptor agonist, and retatrutide adds glucagon receptor agonism as a triple agonist. They differ in which receptor arms they engage rather than in fundamental class.
Why do GLP-1 analogs need low-bind labware?: Acylated analogs are surface-active and adsorb to standard glass and plastic at low concentrations, producing apparent potency loss that is a handling artefact rather than compound degradation.
What is cagrilintide's mechanism relative to GLP-1 analogs?: Cagrilintide is a long-acting amylin analog acting at calcitonin and amylin receptor complexes — a satiety-signalling axis distinct from the incretin receptors engaged by GLP-1 analogs.